You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction
|
|---|---|
| Published in |
Cardiovascular Diabetology, July 2017
|
| DOI | 10.1186/s12933-017-0572-0 |
| Pubmed ID | |
| Authors |
Mei-Tzu Wang, Sheng-Che Lin, Pei-Ling Tang, Wang-Ting Hung, Chin-Chang Cheng, Jin-Shiou Yang, Hong-Tai Chang, Chun-Peng Liu, Guang-Yuan Mar, Wei-Chun Huang |
| Abstract |
Previous studies regarding the cardioprotective effects of dipeptidyl peptidase 4 (DPP-4) inhibitors have not provided sufficient evidence of a relationship between DPP-4 inhibition and actual cardiovascular outcomes. This study aimed to evaluate the impact of DPP-4 inhibitors on the survival of diabetic patients after first acute myocardial infarction (AMI). This was a nationwide, propensity score-matched, case-control study of 186,112 first AMI patients, 72,924 of whom had diabetes. A propensity score, one-to-one matching technique was used to match 2672 controls to 2672 patients in the DPP-4 inhibitor group for analysis. Controls were matched based on gender, age, and a history of hypertension, dyslipidemia, diabetes, peripheral vascular disease, heart failure, cerebrovascular accident, end-stage renal disease, chronic obstructive pulmonary disease, and percutaneous coronary intervention. DPP-4 inhibitors improve the overall 3-year survival rate (log rank P < 0.0001), whether male or female. Cox proportional hazard regression showed DPP-4 inhibitor is beneficial in diabetes patients after AMI (HR = 0.86; 95% CI 0.78-0.95), especially in those patients with hypertension (HR = 0.87; 95% CI 0.78-0.97; P = 0.0103) and cerebrovascular disease (HR = 0.83; 95% CI 0.72-0.97; P = 0.018), but without dyslipidemia (HR = 0.78; 95% CI 0.67-0.92; P = 0.0029), without peripheral vascular disease (HR = 0.86; 95% CI 0.78-0.96; P = 0.0047), without heart failure (HR = 0.84; 95% CI 0.73-0.96; P = 0.0106), without end stage renal disease (HR = 0.86; 95% CI 0.77-0.95; P = 0.0035), and without chronic obstructive pulmonary disease (HR = 0.87; 95% CI 0.78-0.97; P = 0.0096). DPP-4 inhibitor therapy improved long-term survival in diabetic patients after first AMI, regardless of gender. |
X Demographics
The data shown below were collected from the profiles of 41 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 17 | 41% |
| United States | 2 | 5% |
| Japan | 2 | 5% |
| Paraguay | 1 | 2% |
| Chile | 1 | 2% |
| Canada | 1 | 2% |
| United Kingdom | 1 | 2% |
| Saudi Arabia | 1 | 2% |
| Unknown | 15 | 37% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 35 | 85% |
| Practitioners (doctors, other healthcare professionals) | 4 | 10% |
| Scientists | 2 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 13% |
| Student > Bachelor | 7 | 13% |
| Researcher | 6 | 11% |
| Student > Ph. D. Student | 6 | 11% |
| Student > Doctoral Student | 4 | 8% |
| Other | 7 | 13% |
| Unknown | 16 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 32% |
| Nursing and Health Professions | 6 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Psychology | 2 | 4% |
| Other | 1 | 2% |
| Unknown | 20 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 August 2017.
All research outputs
#1,631,859
of 25,732,188 outputs
Outputs from Cardiovascular Diabetology
#94
of 1,688 outputs
Outputs of similar age
#30,840
of 325,730 outputs
Outputs of similar age from Cardiovascular Diabetology
#2
of 19 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,688 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,730 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.